Specifically, the combination of FEZF1-AS1 and NSE increased the sensitivity, specificity, and accuracy of distinguishing patients with NSCLC from healthy individuals, compared with FEZF1-AS1 and NSE alone (Table 1). This evidence concerns the gene ENO2 and non-small cell lung carcinoma.